Andrew Lin / 林羣
Mr. Lin has nearly 40 years of experience in biotechnology, asset management, capital markets, and corporate governance. He serves as the Chairman of NUWA Biomedical, TaiRx Biotechnology, and BRIM Biotechnology, bringing extensive expertise in biotechnology. He has held senior positions at Lotus Pharmaceutical and Hasumi International Biotech.
He was formerly the President of J.P. Morgan Securities (Taiwan) Limited and became the first underwriter for a Hong Kong IPO between 2008 and 2009. He served as a Senior Partner at Hong Kong-based SAIF Eagle Fund. He is in senior positions at ABN AMRO, Chicony Chengdu International, and 源泰 Investment.
Mr. Lin has held senior positions in multiple listed companies, including Chairman, CEO, and General Manager, and has served on the board of directors for various companies such as Fubon Life Insurance, Crown Bioscience, EPISTAR, Lite-On IT Corporation, Silitech Technology Corporation, and 104 Corporation.
Current Positions
-
Chairman at BRIM Biotechnology
-
Chairman at TaiRx
-
Chairman at NUWA Biomedical
-
Chairman / Managing Partner at Affinity Capital
-
Independent Director at Fubon Life Insurance
Experience
-
Chairman at Lotus Pharmaceutical
-
CEO at Hasumi International
-
President at Macquarie Group Limited
-
CFO at Liteon Technology
-
CEO at J.P. Morgan Securities (Taiwan) Limited
Education
-
MBA, The University of Chicago
-
M.S. in electrical and computer engineering, the University of Massachusetts at Amherst
